Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

NCT00542880 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

442

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
DRUG: Seretide Diskus (salmeterol/fluticasone) 50/500 μg

Sponsor

AstraZeneca